Hemastatx is committed to bringing innovation to patients with severe and underserved bleeding disorders. Our lead program, HMX-001, is a first-in-class antibody therapy designed to address the root cause of severe bleeding episodes in patients with von Willebrand factor (VWF) disorders.

Preclinical stage biopharmaceutical company, spin off of the European Diabetes Study Center (CeeD), dedicated to developing first-in-class biotherapies against diabetes and metabolic diseases, harvesting the breakthrough potential of the muscle secretome to regulate metabolism, a novel and unexplored approach

Enabling breakthrough medicines achieve the outcomes they were designed for. We unlock the full therapeutic potential of innovative drug candidates through our next-gen nanomedicine delivery platform. We want to establish our biovectors as the universal standard for targeted therapeutic delivery.